Clotblog with Dr Samuel Goldhaber

View all posts »

Rosuvastatin in the prevention of venous thromboembolism

May 29, 2009 11:45 EDT


What are the implications of the JUPITER trial's landmark findings in preventing venous thromboembolism? A 43% highly significant reduction in incidence and no increased bleeding risk with rosuvastatin 20 mg daily compared with placebo.  Where do we go next?  And what do we do now in clinical practice?

Please refer to the epublished JUPITER manuscript:  Glynn RJ et al.  A randomized trial of rosuvastatin in the prevention of venous thromboembolism.  N Engl J Med 2009; March 29.





« Previous Post
Clot is hot at ISTH
Jul 14, 2009 00:00 EDT Next post »
The surgeon general issues a call to action to prevent pulmonary embolism and DVT
Dec 10, 2008 14:23 EST



Your comments
Rosuvastatin in the prevention of venous thromboembolism
# 1 of 4
June 2, 2009 09:14 (EDT)
karen

Given that there are a plethora of statin trials that have already been conducted, it would seem that, even though VTE may not have been a prespecified endpoint, one could go back to these databases and determine whether similar reductions in VTE were demonstrated versus placebo.
# 2 of 4
June 3, 2009 12:31 (EDT)
Menad fatiha

the Virchow triad:
thrombosis is due to three factors-stasis
                      -hypercoaguabilité
                       -hyperviscosity
when you give a cause neuroleptic you demunition stasis by the seimulation nerve in vascular
so it always involve a antiagréguant or heparin with neuroleptics
# 3 of 4
June 17, 2009 11:37 (EDT)
Prof Dr Sadasivan

Der Dr Goldhaber,

DVT is a real threat as we know but this is the first time that we have discovered the statins to have a bearing on it.Congratulations to you from India!

Dr Sadasivan.

# 4 of 4
August 12, 2009 06:55 (EDT)
A G G Turpie
perhaps a secondary prevention trial with a statin particularly in patients with recurrent VTE would be useful 

You must be a member (with full membership) to post a comment.
Already a member?
Enter your login information below:
 Remember me on this computer
Forgot your username and/or password?
        Login        
Enjoy all the benefits of theheart.org

With full membership, you can check out our educational and editorial content, search the site, receive our newsletters, join discussions, download slides and much more.

Membership is free!

    Join now for full access    
Who's Talking
Samuel Z Goldhaber, MD
Professor of Medicine
Harvard Medical School
Director, Venous Thromboembolism Research Group
Co-Director, Anticoagulation Management Service
Cardiovascular Division
Brigham and Women's Hospital
Boston, MA